title: The status of modeled claims.
abstract: The only acceptable modeled claims for costs and outcomes are those that are testable and can be validated in a timeframe that is acceptable to a formulary committee. This issue provides four papers which explore the methodological issues in validation, the UK experience with NICE, the questions a formulary committee should ask of modeled claims, and the role of Big Data in validating modeled claims.
authors.affiliation: a College of Pharmacy, University of Minnesota, MN, USA, and Maimon Research LLC , Tucson , AZ , USA.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Langley
mesh_terms: D004864:Equipment and Supplies / Q000191:economics / Q000592:standards*; D005569:Formularies as Topic; D006801:Humans; D008962:Models, Theoretical; D013222:State Medicine / Q000191:economics / Q000592:standards*; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000379:methods / Q000592:standards*; D006113:United Kingdom
keywords: Credibility; Feedback; Modeled claims